Can an earthworm enzyme boost stroke recovery?

NCT ID NCT07763405

Not yet recruiting Disease control Sponsor: Xinqiao Hospital of Chongqing Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether adding lumbrokinase, an enzyme derived from earthworms, to standard aspirin treatment can improve recovery in people who have had a moderate-to-severe ischemic stroke. Participants receive either lumbrokinase capsules or a placebo, along with aspirin, for up to 90 days. The study measures how many people achieve a good functional outcome (able to live independently) at 90 days, and also tracks any serious bleeding events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lumbrokinase (an enzyme from earthworms) taken as capsules, combined with aspirin
What this could lead to: If effective, this could offer a new oral treatment to improve functional recovery after a moderate-to-severe ischemic stroke, potentially reducing long-term disability.
What could go wrong: This is a phase 4 trial, but results are not yet known. The main risk is increased bleeding, and the benefit over standard aspirin therapy remains unproven until the data are analyzed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE, ACUTE

More trials for these conditions

Other studies related to the condition(s) this trial covers.